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Introduction
Valproic acid (VPA) is a broad spectrum antiepileptic drug used in the treatment of both generalized and partial seizures [1] [2] [3] . Its activities are also extended to bipolar disorder and some neurological conditions including migraine and neuropathic pain [1] [2] [3] . The exact mechanism of action of the drug is uncertain. However, several studies have proposed that VPA potentiates gamma aminobutyric acid (GABA) effects in the central nervous system [1] . Several VPA formulations are available including conventional tablets, enteric coated tablets, sustained-release tablets, capsules, oral solution and intravenous solution. The drug is rapidly and completely absorbed. However, differences in the rate of VPA absorption and bioavailability among formulations have been documented. The available data suggest that the bioavailability of VPA approaches 1.0 for intravenous solution, oral solution and capsules, whereas the bioavailability for sustained-release tablets is approximately 0.8-0.9 [4] . For the rate of absorption, the reported times to maximum concentration (T max ) of VPA for oral solution, enteric coated tablet and sustained-release tablet formulations are 1-2 h, 3-6 h and 10-12 h, respectively [1] .
Approximately 90-95% of VPA is bound to albumin [5, 6] . The binding becomes saturated when VPA concentrations are above 50 mg l À1 , resulting in a disproportionate increase in VPA concentrations [4] . Several factors can affect VPA protein binding such as age, concomitant medications, renal and hepatic diseases and pregnancy status [1, 3] , resulting in a high variability in apparent volume of distribution ranging from 0.1 to 0.5 l kg À1 [4, 7] .
VPA is mainly metabolized by the liver, with only a small amount of unchanged form being excreted in the urine [1] . VPA exhibits high inter-individual variability, particularly when enzyme-inducing or -inhibiting drugs are coadministered [1] . Three routes of VPA metabolism in humans have been proposed, including glucuronide conjugation, β-oxidation in mitochondria and cytochrome P450 (CYP450) mediated metabolism [8] [9] [10] . Of these, the last is considered a minor route of metabolism accounting for only 10% of administered dose [9, 10] . Three isoforms CYP2C9, CYP2A6 and CYP2B6 are known to play a role in desaturation of VPA to the terminal olefin Δ 4 -VPA [6, 11] .
Moreover, the drug has the potential to inhibit CYP2C9 [11, 12] , resulting in increased plasma concentrations of comedications. Glucuronyltransferase (UGT) isoforms participating in VPA metabolism include UGT1A3, 1A4, 1A6, 1A8 and 1A9 [13] . An average clearance value for VPA is 8 ml kg À1 h À1 with a range of 6-10 ml kg À1 h À1 . For halflife, an average value is 10-12 h, with a range of 4-17 h [4] . Higher VPA clearances and shorter half-lives have been reported in children [4] . The drug is slightly removed (<20%) by standard haemodialysis, but is greatly eliminated via high-flux haemodialysis [13] . Given its relatively short half-life, steady state VPA concentrations are usually achieved within 24-48 h. Because VPA has a narrow therapeutic window, therapeutic drug monitoring (TDM) of VPA is a crucial part of drug therapy. The recommended VPA therapeutic range for the treatment of epilepsy is 50-100 mg l À1 . A slightly higher range of 50-125 mg l À1 is proposed for bipolar disorder therapy [4, 14, 15] . VPA levels greater than the recommended range may result in gastrointestinal side effects including nausea, vomiting and diarrhoea [4] . Tremor and thrombocytopenia can occur at higher concentrations. When VPA concentrations exceed 175-200 mg l À1 , CNS toxicity is generally seen [13] . Monitoring of VPA concentrations should be employed in most patients to ensure efficacy and avoid adverse effects. Given the reported diurnal variation in VPA concentrations [16, 17] , trough concentrations in the morning should be used for TDM, as they are the most consistent levels from day to day [13] . Currently, the method used to initiate VPA dosing is to use average VPA parameters obtained in other patients with similar conditions. Subsequently, the dose is modified based on the clinical status of patients. Because of the high variability in VPA pharmacokinetics [4, 5, 13] , the method previously mentioned might result in too high or too low doses of VPA treatment. Moreover, this conventional approach has some limitations when the available VPA concentrations are not at steady state or the sampling time is not appropriate.
A population pharmacokinetic approach with Bayesian estimation allows clinicians to incorporate several factors affecting VPA pharmacokinetics into individualized drug therapy. In addition, this approach is more flexible in clinical settings where difficult situations such as non-steady state drug concentrations or clinically unstable patients are present [5] . Several population pharmacokinetic models for VPA have been reported. Given the continual use of VPA in clinical settings, knowledge concerning factors affecting pharmacokinetic variability of VPA is important. The objectives of this systematic review are to provide information on population pharmacokinetics of VPA and to summarize significant covariates affecting VPA pharmacokinetics which will be of benefit in clinical application and future research.
Methods
Population pharmacokinetic studies of VPA were systematically searched from PubMed and Embase databases from inception to June 2017. The following search terms were employed: (('valproic acid' OR 'sodium valproate' OR 'valpro*' OR 'VPA') AND ('population pharmacokinetic' OR 'pharmacokinetic model*' OR 'nonlinear mixed effect*' OR 'NONMEM')). Reference lists of the identified articles were also checked. In addition, abstracts and non-journal publications were reviewed if they provided sufficient details.
Inclusion criteria
Identified studies were eligible to be included in this review if they met the following criteria:
1. Study population: human studies (healthy volunteers or patients). 2. Treatment: VPA as a studied drug. 3. Analysis: population pharmacokinetic analysis of VPA employing a nonlinear mixed effect modelling approach.
Exclusion criteria
Studies were excluded from this review if:
1. They were review papers or focused on methodology/ algorithm or software/program considerations. 2. The studies were conducted in vitro or in animals. 3. Approaches other than mixed effect modelling were employed. 4. They were published in non-English language articles. 5. Information on methodology or pharmacokinetics was insufficient.
Data Extraction
The following information was extracted from each included article: (i) study characteristics (e.g. types of study, sampling time, number of collected samples, dosage regimen and VPA formulations), target population (patients or healthy subjects), population characteristics (e.g. age and weight range, gender, disease, concomitant medication), and (ii) information on population pharmacokinetic analyses such as structural models, statistical models (i.e. inter-individual and residual variability), parameter estimates, covariates retained in the model as well as their criteria for significance, and approaches employed for model evaluation (e.g. internal or external validation).
Results

Study identification
A total of 103 and 160 studies were identified from PubMed and Embase databases searches, respectively. One additional record was identified from reference lists. Following title and abstract screening, 46 studies were available for eligibility assessment. Of these, 20 studies were excluded based on the exclusion criteria: (i) eleven articles were not population pharmacokinetic studies; (ii) four studies were review articles or methodology considerations; (iii) two studies did not use a mixed effects approach; (iv) one record was a non-English language article; and (v) two studies did not provide sufficient information on methodology or pharmacokinetic parameters. Therefore, a total of 26 publications fulfilled the final criteria for this review. A PRISMA diagram of study identification is presented in Figure 1 .
Study characteristics
All studies were published between 1995 and 2017. Table 1 summarizes the characteristics of each study. Most of the models were developed in patients with epilepsy .
One study reported a model incorporating data from both epileptic and psychiatric patients [39] . One study was conducted in patients with mania [40] . One study was performed in patients with acute VPA poisoning [41] and the other one was conducted in healthy subjects [42] . The sample size of subjects used for model development ranged from 14 to 902. The number of VPA levels per individual for all studies ranged from 1 to 16. The VPA doses of the included studies ranged from 2.4 to 87.9 mg kg À1 d À1 . Use of sustained-release formulation was reported in nine studies [21, 28, 31, 34, 37, 38, [40] [41] [42] . Fluorescence polarization immunoassay (FPIA) and enzyme multiplied immunoassay (EMIT) were used in 57.7% and 15.4% of the studies, respectively.
Population pharmacokinetic models of valproic acid
Most of the included studies aimed at describing variability in VPA pharmacokinetics, that is, to determine the magnitude of both inter-individual variability (IIV) and residual variability (RV), as well as the influence of several covariates on VPA pharmacokinetics. One study investigated VPA protein binding [27] . One study characterized the relationship between total and unbound serum VPA concentration based on the Langmuir equation, taking into account the IIV [29] . Population pharmacokinetics/pharmacodynamics of VPA was performed in two studies (one study determined the optimal concentration of VPA based on clinical characteristics using a receiver operating characteristic (ROC) curve [36] , the other determined the impact of superoxide dismutase 2 (SOD2), glutathione S-transferase mu 1 (GSTM1) and glutathione S-transferase theta 1 (GSTT1) on the relationship between VPA exposure and the risk of γ-glutamyltransferase (γ-GT) elevation [43] ). One study proposed a non-linear model for VPA pharmacokinetics based on protein binding saturation [37] . One study applied population pharmacokinetics to describe the time course of VPA and its metabolites in an overdose situation [41] . Only seven studies provided an application of the proposed models such as dosage recommendations to achieve target level, simulations of VPA concentrations based on the proposed dosage regimens, and γ-GT elevation based on VPA dose and SOD2 polymorphism [20, 23, 30, 34, 38, 40, 43] . Approximately 85% of the studies were TDM studies. Almost all of the studies described VPA pharmacokinetics as a one-compartment model (n = 18). Only three studies reported a two-compartment model. Additionally, a steady state model (C ss = Dose/(CL * τ)) was employed in three studies [19, 20, 44] . Rate of absorption was characterized as a first order process in most of the studies. However, zero order absorption was reported in one study in which liquid oral dosing was administered [34] . Absorption lag time was reported in five studies [21, 34, 36, 42, 43] and enterohepatic circulation (EHC) was reported in one study [42] . Influence of formulation on absorption rate was taken into accounted in six studies [21, 28, 30, 31, 34, 40] . Of these, three studies fixed the absorption rate constant (k a ) at literature values [30, 34, 40] . Elimination was characterized as a linear process, with the exception of two studies in which a dosedependent maximum effect model (DDE) [37] and a Michaelis-Menten kinetics for β-oxidation process [41] were employed. NONMEM software was the most frequently used software for population pharmacokinetic model development. Table 2 summarizes information on population pharmacokinetic models with respect to study type, model structure and model validation.
Several covariates were tested during model development. Age, body weight, gender, co-medication and VPA dose were the most frequently tested covariates, accounted for in 88%, 85%, 77%, 73% and 58% of the studies, respectively. However, gender and age were found to significantly affect VPA pharmacokinetics in only six and seven studies, respectively. CYP2C9 and CYP2C19 genotypes were investigated in two studies [31, 43] . Only one of them found significant effects of CYP2C9 and CYP2C19 genotypes on VPA clearance [31] . Investigated and significant covariates as well as criteria for statistical significance are summarized in Table 3 .
Exponential models (n = 11) were the most frequently used error models for IIV, followed by proportional (n = 10) and additive (n = 2) error models, respectively. For RV, additive (n = 10) and proportional (n = 10) models were the most commonly used, followed by combined proportional and additive (n = 2), and exponential (n = 2) models, respectively. The magnitude of IIV on VPA clearance ranged from 13.4% to 49.1%. Estimated pharmacokinetic parameters, magnitude of IIV and RV as well as relationship between covariates and pharmacokinetic parameters of each study are summarized in Table 4 .
Approximately 65% of the studies evaluated performance of the final models ( Table 2 ). Of these, external datasets were used in nine studies. The sample size of external datasets ranged from 20 to 130 subjects. Five studies evaluated the models by means of internal validation such as bootstrapping, visual predictive check (VPC) or normalized prediction immunoassay; IV, intravenous; LD, loading dose; LLOQ, lower limit of quantification; NR, not reported; SR, sustained release; TDM, therapeutic drug monitoring; %CV, % coefficient of variation; γ-GT, γ-glutamyltransferase distribution error (NPDE). Both internal and external validation were employed in three studies.
Discussion
VPA is one of the most widely used antiepileptic drugs. The drug has also been used to treat bipolar disorder and other neurological conditions. Several pharmacokinetic studies of VPA have been reported. This is the first review article that aimed to summarize knowledge concerning population pharmacokinetics of VPA, focusing on the nonlinear mixed effects modelling approach. Even though VPA is almost completely absorbed, the absorption rate of the drug depends on dosage form. However, among the 15 studies that reported rate of VPA absorption, only six studies accounted for the influence of dosage form on absorption rate constant (k a ) and only four of them were able to estimate the k a values. The ranges of estimated k a values and magnitude of variability were 0.109-0.424 h À1 and 1-36.7%, respectively. The estimated k a values for tablet dosage form are more variable with a range of 1.0-8.14 h À1 and a variability of 11-246%. The high variability in k a (246%) of tablet dosage form is likely due to the limited number of samples per subject (~1.6), resulting in little information during the absorption phase. Additionally, it has been known that VPA concentrations are subject to diurnal variation [13] . Given the wide range of sampling time (1.0-39.3 h), such high variability in k a is not surprising. Estimated population k a values for dosage forms other than conventional and slow-release tablets are not available.
Eleven studies reported estimated values of volume of distribution (V d ). Of these, three studies characterized VPA pharmacokinetics as a two-compartment model. The estimated V d for one-compartment models and peripheral volume of distribution (V p ) for two-compartment models ranged from 8.4 to 23.3 l and 4.08 to 42.1 l, respectively. The variability in V d was relatively high, with the range of 2.1-49.0% and 23.9-101.50% for V d of one-compartment and V p of two-compartment models, respectively. The authors proposed that the high variability in V p (101.50%) could be attributed to the variability in protein binding which was not taken into account in the model [34] . Given that a sparse sampling strategy was employed, it was not possible to estimate the magnitude of IIV in some studies and was therefore set at zero. For the effect of covariates, the reported significant factors influencing V d included body weight, VPA dose and age. V d of VPA increased with body weight and VPA dose. The increase in V d with higher doses could be explained by the saturable protein binding [45] . Regarding protein binding, Dutta et al. [27] reported that a one binding site model best described the VPA protein binding, with the population estimates for number of binding sites (N) and binding site association constant (K) of 1.98 and 15.5 mM À1 , respectively. [19, 20, 44] . Regarding the effect of age, higher CL VPA in young children compared with adults has been reported. However, the effect of age on CL VPA in the children population is controversial. Tanikawa et al. [21] reported the decrease in CL VPA with increasing age up to 12 years, which is consistent with a study by Cloyd et al. [46] in that CL VPA decreases with maturation and reaches adult values around age 14-16 years. Even though, the reason for this finding is unknown, it has been reported that liver volume per unit body weight linearly decreases with increased age throughout childhood [47] . However, El Desoky et al. [25] , Jankovic et al. [26] and Jiang et al. [28, 31] reported a linear relationship between age and CL VPA . They proposed that the increase in CL VPA with increasing age could be explained by the developmental changes in drug metabolism in children. As for gender effect, lower CL VPA in females has been observed in five studies [19, 20, [42] [43] [44] .
As previously mentioned, VPA is mainly metabolized via three routes including glucuronidation, β-oxidation and CYP450 enzymes [8] [9] [10] . Evidence showing lower UDPglucuronosyltransferases activity in females has been documented [48] . Moreover, Ibarra et al. [42] tested the effect of gender on VPA pharmacokinetics incorporating an EHC process and found that the reabsorbed fraction of VPA in women was higher than in men. In addition, a 21.5% increase in CL VPA was observed in women taking contraceptive therapy. The authors proposed that this could be attributed to an inductive effect of ethinylestradiol on glucuronosyltransferase activity. An increase in CL VPA with increasing VPA dose was reported by several studies. One possible explanation for this could be protein binding saturation, resulting in higher free VPA available for elimination. Moreover, a TDM effect could be another factor contributing to the increased CL VPA since individuals with high CL VPA tend to receive a higher dose. To better characterize this non-linearity, Ding et al. [37] compared the ability of three models (i.e. the power exponent model, the dose dependent maximum effect (DDE) model and the protein binding model). The authors found that the DDE model best described VPA data, based on the standard evaluation criteria.
Concomitant drugs commonly found to influence CL VPA included carbamazepine, phenobarbitone and phenytoin. These drugs are enzyme inducers [4, 5] , leading to an increase in CL VPA when co-administered with VPA. The magnitude of CL VPA elevation varies across studies. However, some studies did not find the effects of these enzyme-inducing agents on CL VPA , which might be due to the limited number of subjects using these drugs. In addition, Jiang et al. [31] reported a significant effect of CYP2C9 and CYP2C19 genotypes on CL VPA . Although pathways other than CYP-mediated elimination have been proposed, this finding is of importance in clinical settings where a test for CYP2C9 and CYP2C19 genotypes is available [8] [9] [10] .
In terms of concentration-response relationships, a therapeutic range of VPA of 50-100 mg l À1 in the treatment Stepwise addition (P < 0.05)/backward elimination (P < 0.01)
WT, VPA dose, co-medication on CL 7 Blanco-Serrano et al. [23] WT, age, VPA dose, gender, co-medication (CBZ)
Stepwise addition (P < 0.05) and stepwise deletion (P < 0.01)
WT, VPA dose, co-medication on CL Population pharmacokinetic modeling of valproic acid of epilepsy is widely accepted [4, 5] . However, consensus on such relationship is questioning since this range was based on two small poorly controlled studies of patients on antiepileptic drug polytherapy. Moreover, this relationship does not take into account the active metabolites of VPA, 2-propyl-4-pentanoic acid and 2-propyl-2-pentanoic acid, that contribute to the anticonvulsant activity [49, 50] . Beydoun et al. [49] reported the efficacy of VPA monotherapy in poorly controlled partial epilepsy randomly assigned to high (80-150 mg l À1 ) or low (25-50 mg l À1 ) VPA concentration level groups. They found that patients in the high VPA level group had higher reduction in seizure frequency from baseline as compared to those in the low VPA level group.
However, adverse events, including tremors, thrombocytopenia, diarrhoea, vomiting and anorexia, were significantly higher in the high VPA level group as well. In addition, Panomvana Na Ayudhya et al. reported that seizure uncontrolled paediatric patients had a significantly higher elimination rate constant (K e ) and a significantly shorter half-life of VPA. However, the sample size of this study was relatively small and future study with a larger sample size is required to confirm the results [51] . With regard to psychiatric patients, even though a therapeutic range for mood-stabilizing activity of VPA has not yet been published, several studies reported that a concentration of at least 50 mg l À1 might be required to achieve clinical response in Stepwise addition (P < 0.05) and stepwise deletion (P < 0.05) PK model: WT, BMI, age, gender, co-medication (PNZ, THP, CZP, RPD, HPD, CPZ), VPA dose
Stepwise addition (P < 0.05) and stepwise deletion (P < 0.001) VPA dose and WT on CL/F AIC, Akaike information criterion; BMI, body mass index; BSA, body surface area; BZD, benzodiazepine; CBZ, carbamazepine; CL, clearance; CLO, clobazam; CPZ, chlorpromazine; CZP, clonazepam; ESM, ethosuximide; F E , reabsorbed fraction; GBP, gabapentin; GEN, gender; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1; HPD, haloperidol; K a , absorption rate constant; LTG, lamotrigine; OCP, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; PNZ, perphenazine; PMD, primidone; Q, inter-compartmental clearance; RPD, risperidone; SOD 2 , superoxide dismutase 2; THP, trihexyphenidyl; T lag , lag time; TPM, topiramate; V c , central volume of distribution; V d , volume of distribution; V max , maximum rate of metabolism; V p , peripheral volume of distribution; VPA, valproic acid; WT, weight; ZNS, zonisamide Table 4 A summary of fixed and random effect models described in the included studies (effect of co-medication is bi-therapy, cannot be applied to three or more concomitant medication) Population pharmacokinetic modeling of valproic acid Table 4 (Continued)
No. Study Population pharmacokinetic modeling of valproic acid patients with bipolar disorder [50, [52] [53] [54] [55] . However, these studies were relatively small, with sample sizes ranging from 24 to 59 patients. Further studies with larger sample size are still needed. Only two studies characterized the relationship between VPA concentration levels and therapeutic/toxic effects by means of population pharmacokinetics and pharmacodynamics [36, 43] . For the relationship between VPA exposure and seizure control, Nakashima et al. [36] utilized a logistic regression model to predict the probability of attaining at least 50% seizure frequency reduction. In addition, the authors determined an optimal cut-off point for such probability using the receiver operating characteristic (ROC) curve. Significant predictors for achieving at least 50% seizure frequency reduction included age, seizure types, SCN1A rs3812718 polymorphism and comedication. The optimal VPA trough concentration for each patient can be calculated using the covariate-parameter relationship and the optimal cut-off point with a logit (Pr) value of 0.1 from the proposed population pharmacokinetics/pharmacodynamics models as summarized in Table 4 . For example, the optimal trough concentration for a patient with SCN1A G/G genotype, aged 10 years with generalized seizure, receiving VPA with phenytoin, is estimated to be 92.0 mg l À1 , whereas the optimal trough concentration in patients with the same conditions aged 10 years carrying SCN1A A/A genotype is estimated to be 142.4 mg l À1 . These findings imply that some patients might require VPA trough concentrations of greater than the generally accepted range of 50-100 mg l À1 to achieve at least 50% seizure frequency reduction. Therefore, for patients with poorly controlled seizures, the optimal VPA trough concentrations might be obtained from the proposed population pharmacokinetics/pharmacodynamics model, instead of exclusively relying on the generally accepted range of 50-100 mg l À1 . Regarding the relationship between VPA exposure and the risk of developing toxicity, Ogusu et al. [43] investigated the impact of polymorphisms of antioxidant enzyme genes (SOD2, GSTM1 and GSTT2) on the elevation of γ-GT, an enzyme used as a liver function marker commonly found in hepatocytes and biliary epithelial cells, during VPA therapy. The authors found that SOD2 Val16Ala polymorphism significantly influenced the relationship between VPA exposure and γ-GT elevation and concluded that SOD2 genotyping may play an important role in preventing VPA-induced γ-GT elevation. However, the complexity of their model meant that the influence of enzyme-inducing antiepileptic drugs could not be successfully included. Key aspects pertaining to population pharmacokinetics of VPA for clinical use and future research have been highlighted by this review. For the clinician, VPA therapy could be optimized by population pharmacokinetic models and significant predictors, summarized in this review (Table 4) , with an incorporation of Bayesian estimation to obtain optimal individual doses. However, predictive performance of these published models should be performed in a target population prior to use in clinical settings, particularly equations that were proposed without model validation (Table 2) . Moreover, the choice to adopt these models for clinical use should be based on study design and factors associated with a patient population. For example, a one-compartment model developed from routine monitoring data that incorporated the effect of antiepileptic comedication might be a better choice for patients receiving antiepileptic drug polytherapy. For researchers, this review provides information concerning model structure, population characteristics as well as sources and magnitudes of pharmacokinetic variability. For future studies, a population pharmacokinetic study of VPA in patients with psychiatric and other neurological disorders should be conducted. As for a population pharmacokinetics/pharmacodynamics model, some limitations still exist and future studies are needed to confirm such results. These include a population pharmacokinetics/pharmacodynamics study for seizure control in ethnically diverse populations to ensure the generalizability of the model for seizure control. Moreover, a population pharmacokinetics/pharmacodynamics of VPA in populations other than patients with epilepsy (i.e. patients with bipolar disorder and other psychiatric illness) is still lacking. Finally, more studies in regard to a relationship between VPA exposure and adverse effects, other than an elevation of γ-GT, such as thrombocytopenia by means of population pharmacokinetics/pharmacodynamics are recommended.
Conclusion
Most of the reported population pharmacokinetic studies of VPA were conducted using TDM data, employing a onecompartment model. Significant covariates influencing VPA pharmacokinetics were discussed and summarized. One third of published population pharmacokinetic models for VPA did not perform model validation and need to be evaluated for their predictive performance.
